

Acknowledgements

Preparation of this background paper has been greatly assisted by scientists, medical professionals, journalists, members of the clergy, and other interested parties. Special thanks are extended to members of the Human Gene Therapy Advisory Panel that convened at OTA on September 25, 1984, and others who attended that meeting. Several other groups also deserve special mention. Many workers at the National Institutes of Health, notably Elizabeth Milewski, Rachel Levinson, and Bernard Talbot, critically reviewed some sections of the report. Several members of the Human Gene Therapy Working Group of the Recombinant DNA Advisory Committee at NIH were also quite helpful, including Howard Temin (consultant to the group), Judith Areen, Alexander Capron, James Childress, Samuel Gorovitz, Anne Witherby, Harold Varmus, Arno Motulsky, and Clifford Grobstein. Many at the Food and Drug Administration, in addition to the two representatives on the Advisory Panel, also

reviewed the report. Barbara Filner at the Institute of Medicine of the National Academy of Sciences made several helpful suggestions. Finally, many scientists, health professionals, attorneys, ethicists, journalists, and other interested parties assisted OTA in preparation of the document. These include David Martin, Nancy Wexler, Zsolt Harsanyi, William Nyhan, Jeremy Rifkin, Yale Bohn, Jeffrey Fox, Elena Nightingale, A. L. Beaudet, Kenneth Ryan, Philip Leder, Thomas Maniatis, Duane E. Jeffery, Monte Turner, Mark Skolnick, Leroy Hood, Leon Rosenberg, Leon Kass, and Richard McCormick. Two Scandinavian reviewers also submitted comments: Ole Johan Sandvan and Bertil Wennergren. Those on the OTA staff thank all who assisted us. Those who contributed should not, however, be construed to agree with our conclusions or interpretations, and should not be held responsible for mistakes or other errors.